Moreover, pediatric MASLD is associated with T2DM, cardiovascular metabolism, and renal risk, 157 indicating that GLP-1RA can act as a metabolic modifier, thereby improving prognosis, especially in patients who have difficulty adhering to lifestyle changes
[2] Semaglutide works through several complementary mechanisms: it stimulates insulin secretion from the pancreas when blood glucose levels are elevated, suppresses the release of glucagon (a hormone that raises blood sugar), slows gastric emptying to reduce post-meal glucose spikes, and acts on appetite centres in the brain to promote satiety and reduce food intake
(PubMed) Yuan S, Mason AM, Carter P, Burgess S, Larsson SC
71 Overall, a lot of animal research indicates that GLP-1 receptor agonists can protect dopamine neurons and ease both movement and non-movement symptoms